Central Nervous System (CNS) Lymphoma Market Report 2026

The central nervous system (cns) lymphoma market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to improvements in lymphoma diagnostic accuracy, increased use of high-dose chemotherapy protocols, expansion of hospital oncology infrastructure, advancements in neuro-oncology research, growing availability of corticosteroid therapies.

The central nervous system (cns) lymphoma market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing investments in targeted oncology drugs, rising adoption of personalized cancer treatment, expansion of biomarker-driven therapy selection, growing focus on rare cancer research, increasing clinical trial activity in cns malignancies. Major trends in the forecast period include increasing adoption of targeted immunotherapy treatments, rising use of monoclonal antibody-based therapies, growing integration of precision diagnostics in treatment planning, expansion of combination therapy approaches, enhanced focus on early disease detection.

The growing incidence of psychological disorders is anticipated to drive the growth of the central nervous system (CNS) lymphoma market in the coming years. Psychological disorders are mental health conditions that affect thoughts, emotions, or behaviors, leading to distress or functional impairment. The rise in psychological disorders is influenced by factors such as increased stress levels, social isolation, economic challenges, genetic predisposition, substance abuse, and excessive digital media use. Research into central nervous system (CNS) lymphoma contributes to advancements in neuro-oncology by improving understanding of brain inflammation, immune system interactions, and the blood-brain barrier, which supports the development of improved therapeutic approaches for both cancer and psychological disorders. For instance, in November 2023, according to the National Health Service, a UK-based government department, in 2023, around one in five individuals aged 8 to 25 years were estimated to have a probable mental disorder, impacting 20.3% of those aged 8 to 16 years, 23.3% of individuals aged 17 to 19 years, and 21.7% of those aged 20 to 25 years. Therefore, the increasing incidence of psychological disorders is contributing to the growth of the central nervous system (CNS) lymphoma market.

The increasing prevalence of neurological disorders is expected to further propel the growth of the central nervous system (CNS) lymphoma market going forward. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and peripheral nerves. The rising prevalence of these disorders is driven by factors such as genetic susceptibility, infections, physical trauma, exposure to toxins, autoimmune reactions, and age-related neurodegeneration. Research related to central nervous system (CNS) lymphoma enhances insights into brain function, immune mechanisms, and neuroinflammatory processes, leading to improved diagnostic tools and treatment options that also benefit individuals with neurological disorders. For instance, in August 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, nearly 14 million adults in the United States are projected to be living with Alzheimer’s disease by 2060. Therefore, the growing burden of neurological disorders is expected to support the expansion of the central nervous system (CNS) lymphoma market.

Major companies operating in the central nervous system (CNS) lymphoma market are concentrating on the development of innovative therapies, such as tirabrutinib, for the treatment of primary central nervous system lymphoma. Tirabrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor designed to treat B-cell malignancies, including primary central nervous system lymphoma (PCNSL), by targeting key signaling pathways involved in cancer cell survival and proliferation. For instance, in March 2023, ONO Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to tirabrutinib (ONO-4059) for the treatment of primary central nervous system lymphoma. Tirabrutinib is currently being evaluated in the phase 2 PROSPECT study (NCT04947319) and functions by inhibiting BTK-mediated B-cell receptor signaling, which regulates cellular proliferation, activation, survival, differentiation, and clonal expansion of B cells.

Major companies operating in the central nervous system (cns) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Incyte Corporation, Kazia Therapeutics Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc., Bristol‑Myers Squibb Company, Johnson & Johnson, AstraZeneca plc, Pfizer Inc, BeiGene Ltd, Bayer AG, Spectrum Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Kyowa Kirin Co Ltd, Celltrion Inc, Regeneron Pharmaceuticals Inc, BioNTech SE, PIQUR Therapeutics AG, Curis Inc, TG Therapeutics Inc, Oncoceutics Inc, XEME Biopharma LLC.

North America was the largest region in the central nervous system (CNS) lymphoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system (cns) lymphoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the central nervous system (cns) lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the central nervous system lymphoma market by increasing costs of imported chemotherapeutic agents, monoclonal antibodies, diagnostic imaging equipment, and specialized oncology drugs. Hospitals and cancer treatment centers in North America and Europe are most affected due to reliance on imported pharmaceuticals and advanced treatment technologies, while Asia-Pacific faces higher costs for drug manufacturing inputs. These tariffs are increasing treatment expenses and limiting patient access in some regions. However, they are also encouraging local drug production, regional clinical research investments, and development of cost-optimized oncology therapies.

The central nervous system (cns) lymphoma market research report is one of a series of new reports that provides central nervous system (cns) lymphoma market statistics, including central nervous system (cns) lymphoma industry global market size, regional shares, competitors with a central nervous system (cns) lymphoma market share, detailed central nervous system (cns) lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system (cns) lymphoma industry. This central nervous system (cns) lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Central nervous system (CNS) lymphoma is a rare and aggressive form of lymphoma that develops in the brain or spinal cord. Treatment focuses on targeting and reducing malignant cells within the CNS, relieving symptoms, and improving patient survival through a combination of medications, targeted therapies, and high-energy focused treatment approaches.

The main drugs in the central nervous system (CNS) lymphoma market include monoclonal antibodies, chemotherapeutic agents, and corticosteroids. Monoclonal antibodies are laboratory-engineered proteins designed to replicate the immune system’s ability to recognize and bind to specific targets such as cancer cells, viruses, or inflammatory molecules. These therapies are delivered using various treatment approaches, including chemotherapy, radiation therapy, steroid therapy, and targeted therapy, and are utilized across applications such as hospitals, clinics, ambulatory surgical centers, and other healthcare settings.

The central nervous system (CNS) lymphoma market consists of revenues earned by entities by providing services such as diagnostic service, therapy services, and supportive and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system (CNS) lymphoma market also includes sales of drugs, therapy equipment, supportive therapies, and surgical instruments & tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.